



REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

February 27, 2018 05:07 PM EST

ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the "Investors" section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors

Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media

Adam Pawluk, 202-591-4063
apawluk@jpa.com



REGENXBIO Inc.